• Life Sciences & Care
  • Portfolio Life Sciences & Care
  • Life sciences & care

reMYND nv is a biotech company focusing on disorders of the nervous system, and already has its lead compound in phase II clinical development for Alzheimer’s disease. The company is a spin-off from KULeuven, which has a CRO activity in addition to drug development, helping companies in drug discovery based on its phenotypic screening expertise.

reMYND has a pipeline of molecules targeting novel mechanisms of action and targets for epilepsy, Alzheimer’s, Parkinson’s and Huntington’s, which have the potential to be extended to other rare protein misfolding diseases as well.

Partners in ambition at reMYND

In 2018, reMYND launched a new capital round led by PMV and Korys, with input from existing shareholders such as BNP Paribas Fortis Private Equity, KU Leuven, Gemma-Frisius Fund and Dr Bernard Majoie of the Fondation Fournier-Majoie. Before that, PMV already granted reMYND funding through a convertible loan. The current investor syndicate provided reMYND with funding in 2022 to continue its phase IIa clinical trial in Alzheimer’s with its own resources, strengthening its negotiating position.